

NIH Public Access

Author Manuscript

Trends Microbiol. Author manuscript; available in PMC 2015 March 01.

Published in final edited form as:

Trends Microbiol. 2014 March ; 22(3): 157–163. doi:10.1016/j.tim.2013.12.005.

Emerging roles of immunostimulatory oral bacteria in periodontitis development

Yizu Jiao, **Mizuho Hasegawa**, and **Naohiro Inohara**

Department of Pathology, The University of Michigan Medical School, Ann Arbor, Michigan 48109, USA

Abstract

Periodontitis is a common dental disease which results in irreversible alveolar bone loss around teeth, and subsequent tooth loss. Previous studies have focused on bacteria that damage the host and the roles of commensals to facilitate their colonization. Although some immune responses targeting oral bacteria protect the host from alveolar bone loss, recent studies show that particular host defense responses to oral bacteria can induce alveolar bone loss. Host damaging and immunostimulatory oral bacteria cooperatively induce bone loss by inducing gingival damage followed by immunostimulation. In mouse models of experimental periodontitis induced by either *Porphyromonas gingivalis* or ligature, γ-proteobacteria accumulate and stimulate host immune responses to induce host damage. Here we review the differential roles of individual bacterial groups in promoting bone loss through the induction of host damage and immunostimulation.

Keywords

periodontitis; NOD1; pathobiont; innate immunity; alveolar bone absorption; neutrophil recruitment

Periodontitis is an oral disease associated with outgrowth of multiple bacteria and activation of host immunity

There is a paradox in the way our body handles microbes that live in the oral cavity. Most immune responses are beneficial in that they protect the host against invading pathogens. However, some immune responses to bacteria such as those associated with periodontitis can also damage the host by inducing significant pathology in the oral cavity. Periodontitis is a dental disease affecting billions of patients worldwide that is characterized by chronic gingival inflammation and subsequent alveolar bone loss around the teeth [1,2]. Although colonization of a single bacterium *Aggregatibacter actinomycetemcomitans* is highly associated with aggressive periodontitis in young individuals and adults [3], multiple bacteria are typically involved in the development of chronic periodontitis that affect adult patients [4–7]. Culture-based studies in the last century showed marked changes of the oral bacterial populations during the development of periodontal disease and the important role of 'red complex' bacteria that include *Porphyromonas gingivalis*, *Tannerella forsythia* and

^{© 2013} Elsevier Ltd. All rights reserved.

Corresponding author: Inohara, N. (ino@umich.edu).

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Treponema denticola [4,7]. The difference in the oral bacterial community between healthy and periodontitis patients has been confirmed and characterized in more detail by nonculture based techniques [8–10]. The keystone bacteria that are recently found to be associated with periodontitis also include *Filifactor alocis*, *Treponema*, *Prevotella*, *Selenomonas*, *Peptostreptococcus*, *Anaeroglobus*, *Desulfobulbus* species, Lachnospiraceae, Synergistetes and TM7 species in addition to red complex bacteria [9,10]. Although these newly identified keystone pathogens have not been well characterized, a main feature of the red complex bacteria is the presence of a high level of protease activity. The proteases including *P. gingivalis* gingipains, *T. forsythia* PrtH and *T. denticola* dentilisin proteases are important for virulence [11–14]. The degradation of host extracellular matrix proteins by the bacterial proteases can result in loss of the epithelial barrier in the oral cavity [15,16] and a *P. gingivalis* strain lacking gingipains is impaired in its ability to induce loss of epithelial barrier [16]. Besides these red complex bacteria, other oral commensals play a significant role in periodontitis development. Previous studies with *in vivo* and *in silico* interaction assays focused extensively on metabolic and physical interactions of non-red complex and red complex bacteria and elucidated its importance for dysbiosis in eliciting periodontitis development [5,6,17,18].

Animal models reveal protective responses against periodontitis development

To determine the importance of individual oral bacteria in disease development, experimental animals including mice were infected with individual bacteria isolated from patients with periodontitis, and the sequence of host responses that result in alveolar bone loss [19,20]. Importantly, these animals possess their own commensals that can affect the infection. For example, when specific pathogen-free (SPF) mice are pre-treated with antibiotics such as sulphamethoxazole and trimethoprim which modify the composition of the murine oral microbiota, *P. gingivalis* can reproducibly colonize the oral cavity resulting in alveolar bone loss [21]. Likewise, animal models were used to analyze the interactions among bacteria by combinatory infection which revealed their functional interaction in inducing bone loss [22–24]. These infection models have also shown that host immune responses to oral bacteria are important for periodontitis development. For example, preimmunization of SPF mice with *P. gingivalis* decreases *P. gingivalis* load and the level of alveolar bone loss after infection [13,25]. These observations suggest that adaptive host immunity is important for the elimination of harmful bacteria involved in periodontitis development and protective against alveolar bone loss. The finding that mice deficient in inducible nitric oxide synthase (iNOS), P-selectin or intercellular adhesion molecule 1 (ICAM1)-depleted mice are susceptible to *P. gingivalis* -induced alveolar bone loss [26,27] (Figure 1), suggests that innate immune responses are also important for prevention of alveolar bone loss. Since innate immune systems including complement are critical for host resistance against various pathogens [28], it would be expected that host innate and adaptive immunity prevent periodontitis development through the elimination or control of hostdamaging bacteria. However, recent studies have revealed that the mechanisms involved in periodontitis development are much more complex and that host immunity acts like a double edged sword as described below.

Induction of inflammatory responses results in alveolar bone loss

In addition to protective immune responses that limit bacterial infection, immune responses that target oral bacteria can also result in local loss of alveolar bone. Alveolar bone loss in periodontitis is primarily due to increased bone resorption by osteoclasts that are activated by immunostimulation from oral bacterial components [29]. Differentiation of osteoclasts is also induced by RANK activation following sequential immune responses to oral bacterial

Jiao et al. Page 3

components [30] (Figure 1). The importance of immune responses to bacterial components in alveolar bone loss is further supported by the requirement of interferon- γ (IFN- γ) and interleukin-6 (IL-6), inflammatory molecules that are induced by bacterial stimuli and enhances inflammatory responses [31, 32]. RANK activation is controlled by two critical factors, the RANK ligand (RANKL) and the RANK inhibitor, osteoprotegerin (OPG), whose expression levels in activated CD4⁺ T cells, B cells and osteoblasts are regulated by the inflammatory cytokines tumor necrosis factor (TNF) and IL-1 [31,33–36]. The dominant source of RANKL may appear to be activated T and B cells, because SCID, β2 macrogloblin and RAG-1 deficient mice show a marked decrease of alveolar bone loss in the ligature model [31, 37]. The main sources of the inflammatory cytokines TNF and IL-1, in response to stimulatory bacterial molecules which are recognized by pattern-recognition receptors (PRR), are neutrophils and monocytes/macrophages (see Glossary) [38]. These phagocytic cells express innate immune receptors Toll-like receptor 2 (TLR2), C3aR and C5aR at high levels and mice lacking these proteins exhibit reduction of alveolar bone loss in experimental periodontitis models [39–42]. C3aR and C5aR are the receptors for processed complement factors that are produced through activation of bacteria-stimulated classical and alternative complement pathways as well as the lectin-dependent pathway [28]. In addition, *P. gingivalis* can induce C3 and C5 processing by gingipains [43]. Activation of C3aR and C5aR in immune cells induces chemotactic migration of phagocytes similar to that induced via the receptors for CXCL and CCL chemokines that are secreted from gingival tissues in response to bacterial stimulation [28]. The migration of neutrophils from blood to stimulated gingival tissues also requires several adhesive molecules including ICAM-1 and lymphocyte function-associated antigen 1 (LFA-1) whose interaction is controlled by Del-1, an IL-17 regulated protein [44]. Neutrophil recruitment to damaged gingival sites is also triggered by bacterial stimulation of NOD1 [37]. NOD1 is an innate immune receptor that mediates neutrophil recruitment by inducing the secretion of chemokines from non-hematopoietic cells [45,46]. Mice lacking NOD1 show decreased chemokine CXCL1 secretion from the gingival epithelium in a ligature-induced model of periodontitis [37]. Thus, signaling via the innate immune receptors TLR2, NOD1, C3aR and C5aR connect oral bacteria to alveolar bone loss. While these innate immune receptors are important for elimination of invasive pathogens, their role in protective immune responses during inflammation-induced bone loss is still unknown. As stimulation of either NOD1 or C3aR/C5aR induces the recruitment of phagocytic immune cells, they might play synergistic and cooperative roles in the recruitment of cells. Indeed, C3a and C5a enhance TLRdependent cytokine production *in vivo* [40]. Because stimulation of TLR2, but not NOD1, C3aR and C5aR alone, induces TNF and IL-1 production from immune cells, TLR2 might be important for the induction of the inflammatory cytokines downstream of NOD1, C3aR and C5aR. Clearly, additional studies are needed to understand the role of individual host factors in periodontitis.

Experimental periodontitis models have dissected the distinct roles of individual bacterial groups in periodontitis development

P. gingivalis-monocolonized mice, unlike *P. gingivalis*-colonized SPF mice, do not develop periodontitis phenotypes [47]. This indicates that *P. gingivalis* alone is insufficient to induce periodontitis and induction of alveolar bone loss requires additional oral bacteria. Moreover, the studies suggest that beside their impact on facilitating the colonization of host damaging bacteria such as *P. gingivalis*, other bacteria play synergistic roles with keystone pathogens to induce alveolar bone loss. Bacteria-independent gingival damage induced by ligature placement around or between the molars of SPF mice results in alveolar bone loss, whereas germ-free rodents do not develop bone loss when their teeth are ligated [37, 48]. So bone loss induced by ligature placement is also dependent on the oral bacteria and this model

allows dissecting two different roles of oral bacteria in the induction of bone loss: a direct role through the immunostimulation [37] and an indirect role through the colonization of host damaging bacteria. Further analyses with mice lacking PRRs have elucidated differential immunostimulation by individual bacteria.

Individual oral bacteria possess different immunostimulatory activity

Recent studies have revealed that oral bacterial species possess different levels of immunostimulatory activities that can explained by distinct structure, amounts and localization of the bacterial immunostimulatory molecules [37,46,49–50] (Table 1). *A. actinomycetemcomitans*, a causal agent of aggressive periodontitis, is a γ-proteobacterium that produces lipopolysaccharide (LPS) with the highly TLR4-stimulatory moiety, diphospho-type lipid A [49,51]. TLR4 is critical for elimination of *A. actinomycetemcomitans* [52]. Although practically all bacteria express di-acyl and tri-acyl lipoproteins which are the ligands of TLR2/TLR6 and TLR2/TLR1, respectively [53], NOD1 ligands are quite unique in that they are small molecules that are released from particular bacteria [46,54] and stimulate non-hematopoietic cells upon loss of the epithelial barrier in the intestine and oral cavity [37,55]. Because NOD1 ligands are related to *meso*diaminopimelic acid (*m*DAP)-type peptidoglycan that does not exist in many oral bacteria including *Fusobacterium* and *Streptococcus*, only particular groups of bacteria stimulate NOD1 [46,56]. Bacteroidetes species including *P. gingivalis* possesses low level of NOD1 stimulatory activity, although they produce *m*DAP-type peptidoglycan [37,46,57]. However, Pasturellaceae species *A. actinomycetemcomitans* and the related mouse commensal NI1060 possess and release peptidoglycan with high NOD1-stimulatory activity which is critical for induction of alveolar bone loss [37]. The different levels of NOD1-stimulatory activity released from individual bacteria is dependent on recycling and degradation pathways of peptidoglycan, because dominant NOD1 ligands are produced by peptidoglycan-cleaving enzymes [46,58–60].

Bacteria produce multiple immunostimulatory molecules that may function as redundant stimuli. Injection of LPS preparations including γ-proteobacteria and *P. gingivalis* into the gingival tissue induces alveolar bone loss [61,62]. However, TLR4 is dispensable for induction of alveolar bone loss in the ligature-induced periodontitis model, although the dominant bacterium NI1060 is one γ-proteobacteria that possesses highly TLR4-stimulatory diphospho lipid A LPS (Table 1) [37,49]. This might be explained by the relatively low sensitivity of gingival cells to LPS *in vivo* and *in situ* [37]. However, LPS preparations of Bacteroidetes species including *P. gingivalis* that effectively induce alveolar bone loss [61,62], possess LPS molecules that contain the monophospho-type lipid A motif that poorly stimulate TLR4 ascompared with diphospho-type lipid A LPS [49, 63]. Indeed, TLR4 deficient and wild-type mice show similar levels of *P. gingivalis* load after subcutaneous infection [64]. Purified LPS preparations are often contaminated with other immunostimulatory molecules such as lipoproteins and peptidoglycan fragments that serve as ligands of TLR2 and NOD1, respectively [65,66]. Thus, the ability of LPS preparations to induce bone loss should be verified by the use of synthetic molecules that are free from contamination with other PRR ligands [63,66]. By infecting SPF mice with *P. gingivalis*, TLR2, C3aR and C5aR were shown to be important for immune responses that results in alveolar bone loss [39–42]. However, *P. gingivalis*-infected mice contain multiple γproteobacteria in the oral cavity [47]. Because *P. gingivalis* can induce alveolar bone loss by promoting synergistic interactions between complement and TLRs *in vivo* [40], it is possible that stimulation of other PRRs such as NOD1 is triggered by coexisting mouse commensals. Further analyses using germ-free mice lacking specific PRRs colonized with individual oral bacteria are required to understand the role of individual PRRs in periodontitis. It is also known that bacteria have different sensitivity to complement-mediated immunity [67]. For

example, capsular polysaccharides and O structures of LPS confer resistance against both classical and alternative complement pathways. Moreover, many oral bacteria including *P. gingivalis* possess the ability to interfere with complement systems [28,67]. Therefore, it is possible that the bacterial composition affects activation of C3a- and C5a-mediated pathways in the oral cavity.

The distinct roles of host-damaging and immunostimulatory bacteria in periodontitis

The low NOD1-immunostimulatory activity of red complex bacteria led to the hypothesis that periodontitis development requires both host damage and immunostimulation. In this model, translocation of bacterial components such as NOD1 ligands is triggered by loss of the epithelial barrier that is caused by host damaging red complex (Figure 1). Accumulation of bacteria that possess a high potential to stimulate host immune responses during or after the loss of the epithelial barrier appear to be important for alveolar bone loss. Healthy adult mice have no significant NOD1-stimulatory activity in the oral cavity as the dominant bacteria are largely non-NOD1-stimulatory [57]. Subversion of host immunity by keystone pathogens and other members of the oral microbiota promotes the accumulation of immunostimulatory pathobionts and establishment of dysbiosis that results in alveolar bone loss [2,6,47] (Figure 2). Thus, keystone pathogens can avoid host immune responses and by doing so they promote the accumulation of pathobionts that induce host immune responses that are responsible for pathological alveolar bone loss. Accumulation of NOD1-stimulatory NI1060 by bacteria-independent gingival damage is critical for alveolar bone loss in the mouse ligature-induce periodontitis model [37]. NI1060 is a species related to *A. actinomycetemcomitans* - and *A. actinomycetemcomitans* also possesses high NOD1 stimulatory activity, suggesting that *A. actinomycetemcomitans*-mediated alveolar bone loss in humans is also mediated by NOD1. Therefore, microbiota transition induced by host damage is also important and results in accumulation of NOD1-stimulatory activity in the oral cavity. However, the kinetics of NOD1-stimulatory activity in the oral cavity of periodontitis patients is unknown. Taxonomic classification of oral bacteria suggests that particular bacteria in the non-red color complex might possess high immunostimulatory activity which is important for alveolar bone loss (Table 1). The importance of the preexistence of immunostimulatory bacteria before colonization of host damaging bacteria has been reported in other disease models. For example, the intestinal microbiota already contains high numbers of γ-proteobacterial commensals that possess immunostimulatory activity, and loss of epithelial barrier by a host damaging bacterium triggers the translocation of immunostimulatory commensals [55]. Therefore, it is possible that immunostimulatory bacteria might preexist prior to accumulation of host damaging red complex bacteria in humans during periodontitis development.

Importantly, recent studies suggest a model in which two bacterial functions, namely host damage and immunostimulation act synergistically to induce periodontitis. In this model, the role of host damaging bacteria is to promote the translocation of immunostimulatory bacteria or bacterial components that result in alveolar bone loss. In the hypothesis, *A. actinomycetemcomitans* is a unique bacterium. Inoculation of *A. actinomycetemcomitans* alone induces alveolar bone loss in the SPF mouse model, whereas mouse NI1060 requires host damage to induce alveolar bone loss [37,52,68]. *A. actinomycetemcomitans* produces leukotoxin that damages host cells [3,69]. Therefore, *A. actinomycetemcomitans* is capable of inducing tissue damage in the oral cavity and providing immunostimulation via NOD1, although further investigation using *A. actinomycetemcomitans*-monoclonized mice is required to conclude that these two distinct functions of *A. actinomycetemcomitans* are sufficient to induce alveolar bone loss. This dual function of *A. actinomycetemcomitans*

might explain why accumulation of *A. actinomycetemcomitans* alone is sufficient to induce aggressive periodontitis [3]. The latter notion is also supported by the fact that particular strains (e.g. JP2) which produce high amounts of host cell-damaging leukotoxin are more tightly associated with aggressive periodontitis [69]. Importantly, culture and non-culture based studies demonstrate that *Aggregatibacter* species are also preferentially found in some chronic periodontitis patients [4,9]. Therefore, in the presence of host damaging red complex bacteria, *A. actinomycetemcomitans* strains that secrete lower amounts of leukotoxin are possible sources of NOD1 ligands and may stimulate host immunity. It will be interesting to test if *Aggregatibacter* strains are involved in the development of chronic periodontitis and whether strains isolated from patients with chronic and aggressive periodontitis have different levels of leukotoxin that correlate with disease severity.

Concluding remarks

As described above, several innate immune receptors including TLR2, TLR4, NOD1, C3aR, and C5aR have been identified to be important for alveolar bone loss in mouse models. However, the etiology of human periodontitis is more complex and the roles of these innate immunity genes in human periodontal disease have not been addressed yet (Box 1). Host damaging bacteria that produce high levels of proteases and gingival damage are taxonomically diverse (Bacteroidetes and Spirochaetes). Likewise, bacteria that possess high levels of NOD1-stimulatory activity as well as bacteria that are resistant against complement are diverse [46, 55, 67]. A better understanding of the roles of individual bacteria in human periodontitis and their immunostimulatory functions should lead to better therapies for periodontitis patients. In particular, identification of NOD1-stimulatory bacteria in the human oral cavity would be helpful in understanding the role of immunostimulatory activity in patients with periodontitis. Although NOD1 is a cytosolic protein, NOD1-stimulatory bacteria in the oral cavity are not necessarily intracellular pathogens or pathobionts. Previous studies showed that NOD1 signaling can be initiated by extracellular administration of ligands or by mutant strains of *Listeria monocytogenes* that cannot enter the host cytosol [46]. Comprehensive analyses of PRR-specific immunostimulatory activity in individual oral bacteria should provide insight into how individual bacteria affect and modulate host responses that result in alveolar bone loss.

Box 1

Outstanding questions

- **•** How do host immune responses to oral bacteria induce alveolar bone loss in periodontitis?
- **•** What is the molecular basis by which individual oral bacteria stimulate different host immune receptors?
- **•** Why are another type of pathobionts that stimulate host immunity required for periodontitis development?

Finally, colonization and accumulation of immunostimulatory bacteria that cause alveolar bone loss may depend, at least in part, on the presence of non-red complex commensals in addition to red complex bacteria. Therefore, investigation of the interactions between immunostimulatory bacteria and other commensals in the oral cavity should provide novel insight into the mechanism by which microbiota transition affects periodontitis development.

Acknowledgments

The studies in the authors' laboratory are funded by grant R01 DE018503 from the National Institutes of Health. We thank Gabriel Núñez and Aaron Burberry for critical review of the manuscript.

Glossary

References

- 1. Eke PI, et al. Prevalence of periodontitis in adults in the United States: 2009 and 2010. J Dent Res. 2012; 91:914–920. [PubMed: 22935673]
- 2. Darveau RP. Periodontitis: a polymicrobial disruption of host homeostasis. Nat Rev Microbiol. 2010; 8:481–490. [PubMed: 20514045]
- 3. Henderson B, et al. *Aggregatibacter* (*Actinobacillus*) *actinomycetemcomitans*: a triple A* periodontopathogen? Periodontol 2000. 2010; 54:78–105. [PubMed: 20712635]
- 4. Socransky SS, et al. Microbial complexes in subgingival plaque. J Clin Periodontol. 1998; 25:134– 144. [PubMed: 9495612]
- 5. Kolenbrander PE, et al. Oral multispecies biofilm development and the key role of cell–cell distance. Nat Rev Microbiol. 2010; 8:471–480. [PubMed: 20514044]
- 6. Hajishengallis G, Lamont RJ. Beyond the red complex and into more complexity: the polymicrobial synergy and dysbiosis (PSD) model of periodontal disease etiology. Mol Oral Microbiol. 2012; 27:409–419. [PubMed: 23134607]
- 7. Darveau RP, et al. *Porphyromonas gingivalis* as a potential community activist for disease. J Dent Res. 2012; 91:816–820. [PubMed: 22772362]
- 8. Paster BJ, et al. Bacterial diversity in human subgingival plaque. J Bacteriol. 2001; 183:3770–3783. [PubMed: 11371542]

Jiao et al. Page 8

- 9. Griffen AL, et al. Distinct and complex bacterial profiles in human periodontitis and health revealed by 16S pyrosequencing. ISME J. 2012; 6:1176–1185. [PubMed: 22170420]
- 10. Abusleme L, et al. The subgingival microbiome in health and periodontitis and its relationship with community biomass and inflammation. ISME J. 2013; 7:1016–1025. [PubMed: 23303375]
- 11. Saito T, et al. Cloning, expression, and sequencing of a protease gene from *Bacteroides forsythus* ATCC 43037 in *Escherichia coli*. Infect Immun. 1997; 65:4888–4891. [PubMed: 9353083]
- 12. O'Brien-Simpson NM, et al. Role of RgpA, RgpB, and Kgp proteinases in virulence of *Porphyromonas gingivalis* W50 in a murine lesion model. Infect Immun. 2001; 69:7527–7534. [PubMed: 11705929]
- 13. Gibson FC, et al. Prevention of *Porphyromonas gingivalis*-induced oral bone loss following immunization with gingipain R1. Infect Immun. 2001; 69:7959–7963. [PubMed: 11705986]
- 14. Bamford CV, et al. The chymotrypsin-like protease complex of *Treponema denticola* ATCC 35405 mediates fibrinogen adherence and degradation. Infect Immun. 2007; 75:4364–4372. [PubMed: 17591786]
- 15. Katz J, et al. Characterization of *Porphyromonas gingivalis*-induced degradation of epithelial cell junctional complexes. Infect Immun. 2000; 68:1441–1449. [PubMed: 10678958]
- 16. Groeger S, et al. Effects of *Porphyromonas gingivalis* infection on human gingival epithelial barrier function *in vitro*. Eur J Oral Sci. 2010; 118:582–589. [PubMed: 21083619]
- 17. Kuramitsu HK, et al. Interspecies interactions within oral microbial communities. Microbiol Mol Biol Rev. 2007; 71:653–670. [PubMed: 18063722]
- 18. Mazumdar V, et al. Metabolic network model of a human oral pathogen. J Bacteriol. 2009; 191:74–90. [PubMed: 18931137]
- 19. Madden TE, Caton JG. Animal models for periodontal disease. Methods Enzymol. 1994; 235:106– 119. [PubMed: 8057890]
- 20. Graves DT, et al. The use of rodent models to investigate host-bacteria interactions related to periodontal diseases. J Clin Periodontol. 2008; 35:89–105. [PubMed: 18199146]
- 21. Baker PJ, et al. Oral infection with *Porphyromonas gingivalis* and induced alveolar bone loss in immunocompetent and severe combined immunodeficient mice. Arch Oral Biol. 1994; 39:1035– 1040. [PubMed: 7717884]
- 22. Polak D, et al. Mouse model of experimental periodontitis induced by *Porphyromonas gingivalis*/ *Fusobacterium nucleatum* infection: bone loss and host response. J Clin Periodontol. 2009; 36:406–410. [PubMed: 19419440]
- 23. Daep CA, et al. Structural dissection and *in vivo* effectiveness of a peptide inhibitor of *Porphyromonas gingivalis* adherence to *Streptococcus gordonii*. Infect Immun. 2011; 79:67–74. [PubMed: 21041492]
- 24. Settem RP, et al. *Fusobacterium nucleatum* and *Tannerella forsythia* induce synergistic alveolar bone loss in a mouse periodontitis model. Infect Immun. 2012; 80:2436–2443. [PubMed: 22547549]
- 25. Gibson FC, et al. *Porphyromonas gingivalis*-specific immunoglobulin G prevents *P. gingivalis*elicited oral bone loss in a murine model. Infect Immun. 2004; 72:2408–2411. [PubMed: 15039370]
- 26. Fukada SY, et al. iNOS-derived nitric oxide modulates infection-stimulated bone loss. J Dent Res. 2008; 87:1155–1159. [PubMed: 19029085]
- 27. Baker PJ, et al. Adhesion molecule deficiencies increase *Porphyromonas gingivalis*-induced alveolar bone loss in mice. Infect Immun. 2000; 68:3103–33107. [PubMed: 10816450]
- 28. Ricklin D, et al. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010; 11:785–797. [PubMed: 20720586]
- 29. Sveen K, Skaug N. Bone resorption stimulated by lipopolysaccharides from *Bacteroides*, *Fusobacterium* and *Veillonella*, and by the lipid A and the polysaccharide part of *Fusobacterium* lipopolysaccharide. Scand J Dent Res. 1980; 88:535–542. [PubMed: 7017892]
- 30. Kikuchi T, et al. Cot/Tpl2 is essential for RANKL induction by lipid A in osteoblasts. J Dent Res. 2003; 82:546–550. [PubMed: 12821717]

- 31. Baker PJ, et al. $CD4^+$ T cells and the proinflammatory cytokines gamma interferon and interleukin-6 contribute to alveolar bone loss in mice. Infect Immun. 1999; 67:2804–2809. [PubMed: 10338484]
- 32. Tanaka T, et al. Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases. Int J Biol Sci. 2012; 8:1227–1236. [PubMed: 23136551]
- 33. Yasuda H, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesisinhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 1998; 95:3597– 3602. [PubMed: 9520411]
- 34. Kawai T, et al. B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am J Pathol. 2006; 169:987–998. [PubMed: 16936272]
- 35. Simonet WS, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997; 89:309–319. [PubMed: 9108485]
- 36. Teng YT, et al. Gamma interferon positively modulates *Actinobacillus actinomycetemcomitans*specific RANKL⁺ CD4⁺ Th-cell-mediated alveolar bone destruction in vivo. Infect Immun. 2005; 73:3453–3461. [PubMed: 15908374]
- 37. Jiao Y, et al. Induction of bone loss by pathobiont-mediated NOD1 signaling in the oral cavity. Cell Host Microbe. 2013; 13:595–601. [PubMed: 23684310]
- 38. Takeuchi O, et al. Pattern recognition receptors and inflammation. Cell. 2010; 140:805–820. [PubMed: 20303872]
- 39. Liang S, et al. The C5a receptor impairs IL-12-dependent clearance of *Porphyromonas gingivalis* and is required for induction of periodontal bone loss. J Immunol. 2011; 186:869–877. [PubMed: 21149611]
- 40. Abe T, et al. Local complement-targeted intervention in periodontitis: proof-of-concept using a C5a receptor (CD88) antagonist. J Immunol. 2012; 189:5442–5448. [PubMed: 23089394]
- 41. Papadopoulos G, et al. Macrophage-specific TLR2 signaling mediates pathogen-induced TNFdependent inflammatory oral bone loss. J Immunol. 2013; 190:1148–1157. [PubMed: 23264656]
- 42. Aoyama N, et al. Toll-like receptor-2 plays a fundamental role in periodontal bacteria-accelerated abdominal aortic aneurysms. Circ J. 2013; 77:1565–1573. [PubMed: 23412709]
- 43. Popadiak K, et al. Biphasic effect of gingipains from *Porphyromonas gingivalis* on the human complement system. J Immunol. 2007; 178:7242–7250. [PubMed: 17513773]
- 44. Eskan MA, et al. The leukocyte integrin antagonist Del-1 inhibits IL-17-mediated inflammatory bone loss. Nat Immunol. 2012; 13:465–473. [PubMed: 22447028]
- 45. Masumoto J, et al. NOD1 acts as an intracellular receptor to stimulate chemokine production and neutrophil recruitment *in vivo*. J Exp Med. 2006; 203:203–213. [PubMed: 16418393]
- 46. Hasegawa M, et al. Differential release and distribution of NOD1 and NOD2 immunostimulatory molecules among bacterial species and environments. J Biol Chem. 2006; 281:29054–29063. [PubMed: 16870615]
- 47. Hajishengallis G, et al. Low-abundance biofilm species orchestrates inflammatory periodontal disease through the commensal microbiota and complement. Cell Host Microbe. 2011; 10:497– 506. [PubMed: 22036469]
- 48. Rovin S, et al. The influence of bacteria and irritation in the initiation of periodontal disease in germ-free and conventional rats. J Periodontal Res. 1966; 1:193–204. [PubMed: 4225530]
- 49. Bryant CE, et al. The molecular basis of the host response to lipopolysaccharide. Nat Rev Microbiol. 2010; 8:8–14. [PubMed: 19946286]
- 50. Jain S, et al. A novel class of lipoprotein lipase-sensitive molecules mediates Toll-like receptor 2 activation by *Porphyromonas gingivalis*. Infect Immun. 2013; 81:1277–1286. [PubMed: 23381996]
- 51. Masoud H, et al. Investigation of the structure of lipid A from *Actinobacillus actinomycetemcomitans* strain Y4 and human clinical isolate PO 1021-7. Eur J Biochem. 1991; 200:775–781. [PubMed: 1915349]
- 52. Lima HR, et al. The essential role of toll like receptor-4 in the control of *Aggregatibacter actinomycetemcomitans* infection in mice. J Clin Periodontol. 2010; 37:248–254. [PubMed: 20149215]

- 53. Takeda K, et al. Recognition of lipopeptides by Toll-like receptors. J Endotoxin Res. 2002; 8:459– 463. [PubMed: 12697090]
- 54. Fujimoto Y, et al. Peptidoglycan as NOD1 ligand; fragment structures in the environment, chemical synthesis, and their innate immunostimulation. Nat Prod Rep. 2012; 29:568–579. [PubMed: 22370813]
- 55. Hasegawa M, et al. Nucleotide-binding oligomerization domain 1 mediates recognition of *Clostridium difficile* and induces neutrophil recruitment and protection against the pathogen. J Immunol. 2011; 186:4872–4880. [PubMed: 21411735]
- 56. Schleifer KH, et al. Peptidoglycan types of bacterial cell walls and their taxonomic implications. Bacteriol Rev. 1972; 36:407–477. [PubMed: 4568761]
- 57. Hasegawa M, et al. Transitions in oral and intestinal microflora composition and innate immune receptor-dependent stimulation during mouse development. Infect Immun. 2010; 78:639–650. [PubMed: 19933833]
- 58. Höltje JV. Growth of the stress-bearing and shape-maintaining murein sacculus of *Escherichia coli*. Microbiol Mol Biol Rev. 1998; 62:181–203. [PubMed: 9529891]
- 59. Nigro G, et al. Muramylpeptide shedding modulates cell sensing of *Shigella flexneri*. Cell Microbiol. 2008; 10:682–695. [PubMed: 18042252]
- 60. Pradipta AR, et al. Characterization of natural human nucleotide-binding oligomerization domain protein 1 (NOD1) ligands from bacterial culture supernatant for elucidation of immune modulators in the environment. J Biol Chem. 2010; 285:23607–23613. [PubMed: 20519512]
- 61. Nair BC, et al. Biological effects of a purified lipopolysaccharide from *Bacteroides gingivalis*. J Periodontal Res. 1983; 18:40–49. [PubMed: 6222173]
- 62. Lino Y, et al. The bone resorbing activities in tissue culture of lipopolysaccharides from the bacteria *Actinobacillus actinomycetemcomitans*, *Bacteroides gingivalis* and *Capnocytophaga ochracea* isolated from human mouths. Arch Oral Biol. 1984; 29:59–63. [PubMed: 6362631]
- 63. Fujimoto Y, et al. Innate immunomodulation by lipophilic termini of lipopolysaccharide; synthesis of lipid As from *Porphyromonas gingivalis* and other bacteria and their immunomodulative responses. Mol Biosyst. 2013; 9:987–996. [PubMed: 23429860]
- 64. Burns E, et al. Cutting Edge: TLR2 is required for the innate response to *Porphyromonas gingivalis*: activation leads to bacterial persistence and TLR2 deficiency attenuates induced alveolar bone resorption. J Immunol. 2006; 177:8296–82300. [PubMed: 17142724]
- 65. Travassos LH, et al. Toll-like receptor 2-dependent bacterial sensing does not occur via peptidoglycan recognition. EMBO Rep. 2004; 5:1000–1006. [PubMed: 15359270]
- 66. Chamaillard M, et al. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat Immunol. 2003; 4:702–707. [PubMed: 12796777]
- 67. Rautemaa R, et al. Complement-resistance mechanisms of bacteria. Microbes Infect. 1999; 1:785– 794. [PubMed: 10816084]
- 68. Garlet GP, et al. *Actinobacillus actinomycetemcomitans*-induced periodontal disease in mice: patterns of cytokine, chemokine, and chemokine receptor expression and leukocyte migration. Microbes Infect. 2005; 7:738–747. [PubMed: 15850760]
- 69. Diaz R, et al. Characterization of leukotoxin from a clinical strain of *Actinobacillus actinomycetemcomitans*. Microb Pathog. 2006; 40:48–55. [PubMed: 16414241]
- 70. Bostanci N, Belibasakis GN. *Porphyromonas gingivalis*: an invasive and evasive opportunistic oral pathogen. FEMS Microbiol Lett. 2012; 333:1–9. [PubMed: 22530835]

Highlights

- **•** The host mounts beneficial and harmful immune responses to oral bacteria.
- **•** Innate immune receptors have a critical role in alveolar bone resorption.
- **•** Host damaging and immunostimulatory bacteria have different roles in periodontitis development.
- **•** Individual oral bacteria have different immunostimulatory activity.

Figure 1. Models for host protective and damaging immune responses to oral bacteria in periodontitis

Alveolar bone loss in periodontitis is primarily associated with immune responses to oral bacteria. The immune responses provide protection against translocated bacteria (T) but also mediate alveolar bone resorption which is harmful to host tissues. Host protective immune responses include elimination of pathogens by phagocytic cells (P) and production of antigen-specific immunoglobulin (IGs) which are mediated by antigen presenting phagocytic cells and activated T cells (actT). Inducible NO synthase (iNOS) is also known to be involved in host protective immune responses. The number of bone absorbing osteoclasts increase at sites below the damaged gingiva during periodontitis development. In the model, host damaging red complex bacteria (R) damage the epithelial barrier function. The epithelial damage allows the translocation of harmful bacteria or immunostimulatory bacterial components into the gingival tissue. NOD1 ligands are released from particular types of oral bacteria (N) which induces recruitment of phagocytotic cells to the damaged gingiva via induction of chemokines such as CXCLs and CCLs (e.g. IL-8 and CCL3, respectively). Translocated bacteria (T) are eliminated by phagocytosis and other mechanisms through recruited immune cells, bacterial opsonization, and complement activation. A red complex bacterium such as *P. gingivalis* possesses the ability to process complement factors. The processed complement factors further induce recruitment of myelomonocytic cells to the lesion. IL-17 inhibits expression of Del-1 that interferes with neutrophil adhesion and molecule-dependent neutrophil recruitment. Some myelomonocytic cells are major sources of immunostimulatory molecules which facilitate the development of secondary immune responses to the bacteria. Immunization against *P. gingivalis* is shown to

protect hosts from alveolar bone loss. Myelomonocytic cells also release bone loss-inducing inflammatory cytokines, TNF and IL-1, upon bacterial stimulation of PRRs such as TLR2. RANKL is expressed on activated T, B cells and osteoblasts that are stimulated by these inflammatory cytokines, T cells, and is important for alveolar bone loss in experimental periodontitis models. Therefore, protective immune responses that are activated to eliminate translocated bacteria can also damage the host by the induction of alveolar bone loss.

Figure 2. Distinct roles of host damaging and immunostimulatory bacteria in the development of periodonditis

As shown in Figure 1, host immune responses to oral bacteria are critical for periodontitis development. A particular group of periodontitis-associated keystone pathogens possess the ability to subvert and escape recognition by the host immune system via several mechanisms including intracellular invasion and blockage of host immune signaling [70]. The latter events are likely important for keystone pathogens to establish a dysbiotic bacterial community by avoiding their elimination in the oral cavity. In addition, another type of commensal bacteria is recognized by the host innate immune system to elicit inflammatory responses that result in bone loss. NOD1 ligands are immunostimulatory molecules that are released from bacteria and therefore they can stimulate immune responses remotely from the bacteria. Thus, a model is proposed by which two distinct bacterial groups, namely host damaging (keystone pathogens) and immunostimulatory such as NOD1-stimulatory bacteria act synergistically to induce periodontitis. In the model, keystone pathogens possess the ability to induce damage to the epithelial barrier via virulence factors such as proteases (red complex bacteria) and/or toxins (*A. actinomycetemcomitans*) which enable immunostimulatory bacterial molecules such as NOD1 ligands and/or bacteria to translocate deeper into the tissue and to elicit inflammatory responses and bone loss.

ligand activity; +/-, >5 and 2 ×10⁹ kU/CFU for NOD1 and NOD2, respectively; +, >100, 10, and 5 kU/10⁹ CFU for TLR4, NOD1 and NOD2, respectively; ++, >20kU/10⁹ CFU for NOD1. The number of 9 CFU for NOD1. The number of 9 CFU for TLR4, NOD1 and NOD2, respectively; ++, >20kU/10 bacterial species whose individual PRR stimulatory activity have been determined are listed afterwards in parentheses. bacterial species whose individual PRR stimulatory activity have been determined are listed afterwards in parentheses. 9 kU/CFU for NOD1 and NOD2, respectively; $+$, >100 , 10, and 5 kU/10 ligand activity; +/–, >5 and 2 ×10

 $\boldsymbol{b}_{\text{Predicted}}$ from the genomic sequences of representative species. *Predicted from the genomic sequences of representative species.*

 α Known to have resistant strains for complement activation and/or immunization $(+)$ [67]. Listeria species are intracellular pathogens and therefore resistant to complement activation. *c*Known to have resistant strains for complement activation and/or immunization (+) [67]. *Listeria* species are intracellular pathogens and therefore resistant to complement activation.

 d some Actinomycetales species possess non-mesoDAP type pepidoglycan, so they lack high NOD1 stimulatory activity [62]. *d*Some Actinomycetales species possess non-mesoDAP type pepidoglycan, so they lack high NOD1 stimulatory activity [62].

 e Not tested.

Table 1

NIH-PA Author Manuscript

NIH-PA Author Manuscript